Hospital-Acquired Infection Therapeutics Market by Drug Types (Antibacterial, Antifungal and Antiviral Drugs), Clinical Pipeline Analysis of Phase 1, 2 and 3 Drugs (Amikacin Inhale, CAZ AVI Ceftolozane, Dalvance, Delafloxacin, Eravacycline, MK-3415A, Oritavancin, Plazomicin, Surotomycin, Tedizolid), and Indications (Blood Stream Infections, Gastrointestinal Disorders, HAP, SSIs, UTIs) and Forecast 2017-2021

Hospital-Acquired Infection Therapeutics Market by Drug Types (Antibacterial, Antifungal and Antiviral Drugs), Clinical Pipeline Analysis of Phase 1, 2 and 3 Drugs (Amikacin Inhale, CAZ AVI Ceftolozane, Dalvance, Delafloxacin, Eravacycline, MK-3415A, Oritavancin, Plazomicin, Surotomycin, Tedizolid), and Indications (Blood Stream Infections, Gastrointestinal Disorders, HAP, SSIs, UTIs) and Forecast 2017-2021

Hospital-acquired or hospital-associated infections (HAI) or nosocomial infections are contracted from the environment or staff of a healthcare facility. It can also spread in the hospital environment, nursing home environment, rehabilitation facility, clinic, or other clinical settings. HAIs are caused by viral, bacterial, and fungal pathogens; the most common types are bloodstream infection (BSI), pneumonia (e.g., ventilator-associated pneumonia [VAP]), urinary tract infection (UTI), and surgical site infection (SSI). While antibiotic drugs to treat diseases caused by gram-positive MRSA are available, few effective drugs are available for Acinetobacter bacteria that are evolving and becoming immune to existing antibiotics. The major types of hospital infections prevalent worldwide are hospital-acquired pneumonia, urinary tract infections and surgical site infections. Hospital infections are mainly treated with antimicrobial drugs that help patients suffering from bacterial, viral or other microbial infections.

The global hospital-acquired infection therapeutics market report estimates the market size (Revenue USD million – 2014 to 2021) for key market segments based on the drug type (antibacterial, antifungal and antiviral drugs), clinical pipeline analysis of phase 1, 2 and 3 drugs (Amikacin Inhale, CAZ AVI Ceftolozane, Dalvance, Delafloxacin, Eravacycline, MK-3415A, Oritavancin, Plazomicin, Surotomycin, Tedizolid), indications (blood stream infections, gastrointestinal disorders, HAP, SSIs, UTIs, etc.), and forecasts growth trends (CAGR% – 2017 to 2021).

The global hospital-acquired infection therapeutics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global hospital-acquired infection therapeutics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global hospital-acquired infection therapeutics market and included in this report are Actavis plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., and Sanofi S.A.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Hospital Infection Therapeutics Market

1. Drug Type
1.1. Antibacterial Drugs
1.2. Antifungal Drugs
1.3. Antiviral Drugs

2. Pipeline Analysis
2.1. Amikacin Inhale
2.2. CAZ AVI (Ceftazidime/avibactum)
2.3. Ceftolozane/Tazobactam
2.4. Dalvance (dalbavancin)
2.5. Delafloxacin (RX-3341)
2.6. Eravacycline (TP-434)
2.7. MK-3415A
2.8. Oritavancin
2.9. Plazomicin
2.10. Surotomycin (CB-315)
2.11. Tedizolid (TR-701)

3. Indication Type
3.1. Bloodstream Infections
3.2. Gastrointestinal Disorders
3.3. Hospital-Acquired Pneumonia (HAP)
3.4. Surgical Site Infections (SSIs)
3.5. Urinary Tract Infections (UTIs)
3.6. Other Hospital Infections

4. Company Profiles
4.1. Actavis plc
4.2. AstraZeneca plc
4.3. Bayer AG
4.4. Bristol-Myers Squibb Company
4.5. Cubist Pharmaceuticals, Inc.
4.6. GlaxoSmithKline plc
4.7. Johnson & Johnson
4.8. Merck & Co., Inc.
4.9. Pfizer, Inc.
4.10. Sanofi SA

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*

EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish